Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Axsome Malta Ltd. is currently active in the Biotechnology & Pharmaceuticals technology area, with 2 pending office actions. This number of pending actions suggests a focused patent strategy or a portfolio in its early stages of development. For a company in the biotech sector, these actions represent critical hurdles in securing intellectual property rights for their pharmaceutical innovations.
The prosecution of these matters is split between 2 distinct examiners and 2 distinct art units. This distribution means that each pending action is being evaluated in a different technical and administrative context. The lack of overlap between examiners and art units suggests that the company's technology may span different specialized niches within the broader pharmaceutical field.
JACKSON, SHAWQUIA is the busiest examiner for Axsome Malta Ltd., currently handling 1 busiest examiner pending action. Since the total number of pending office actions is 2, this examiner is responsible for a portion of the company's current workload at the patent office. Practitioners must manage different examiner relationships simultaneously to move the entire pending portfolio toward issuance.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JACKSON, SHAWQUIA | 1 | 78.0% | -3.4% |
| RAMACHANDRAN, UMAMAHESWARI | 1 | 54.8% | +53.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18937105 | CARBAMOYL PHENYLALANINOL COMPOUNDS AND USES THEREOF | JACKSON, SHAWQUIA | — |
| 18819015 | METHODS OF ADMINISTERING SOLRIAMFETOL TO LACTATING WOMEN | RAMACHANDRAN, UMAMAHESWARI | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18819015 | METHODS OF ADMINISTERING SOLRIAMFETOL TO LACTATING WOMEN | RAMACHANDRAN, UMAMAHESWARI | — |
| Art Unit | Apps |
|---|---|
| 1626 | 1 |
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18937105 | CARBAMOYL PHENYLALANINOL COMPOUNDS AND USES THEREOF | JACKSON, SHAWQUIA | 1626 | §101Other | Non-Final OA | — | Pending | Nov 05, 2024 |
| 18819015 | METHODS OF ADMINISTERING SOLRIAMFETOL TO LACTATING WOMEN | RAMACHANDRAN, UMAMAHESWARI | 1627 | §103§112Other | Non-Final OA | — | Pending | Aug 29, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAxsome Malta Ltd. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Shawquia Jackson has the most, with 1 of Axsome Malta Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
